Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

INTRODUCTION: Phase III trials and their open-label extensions have established the efficacy of tildrakizumab in moderate-to-severe plaque psoriasis, but real-world evidence beyond 3 years of treatment is lacking. We assessed the long-term effectiveness, drug survival, and safety of tildrakizumab in routine clinical practice up to 5 years of follow-up. METHODS: A total of 1354 adult patients with moderate-to-severe psoriasis, treated with tildrakizumab for at least 16 weeks, were enrolled across 17 Italian Dermatology Units. Effectiveness was assessed as the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90, PASI 100, and absolute PASI ≤ 2 between week 16 and year 5. Drug survival was estimated by the Kaplan-Meier method, and multivariable logistic regression was used to identify baseline predictors of complete skin clearance. RESULTS: After 1 year of treatment, PASI 90, PASI 100, and PASI ≤ 2 were achieved by 74.0%, 57.2%, and 90.6% of patients, respectively, and responses were maintained through year 5 (87.3%, 76.2%, and 93.7%) in the 63 patients evaluable as observed. Overall drug survival was 92.0% at year 1 and 78.2% at year 5. A short disease duration was the only independent predictor of PASI 100, whereas obesity and cardiometabolic comorbidities did not impair response. No new safety signals emerged. CONCLUSIONS: In this 5-year real-world analysis, tildrakizumab maintained deep responses and high persistence across comorbid and difficult-to-treat subgroups, while short disease duration independently predicted complete clearance.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-11-17
DOI
https://doi.org/10.1007/s13555-026-01984-8
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

Diego Orsini, Luca Mastorino, Martina Maurelli, Simone Ribero et al.
3 links
Dermatology and Therapy
Psoriasis: Treatment and Pathogenesis
article

Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

Diego Orsini, Luca Mastorino, Martina Maurelli, Simone Ribero, Francesco Loconsole, Angelo Valerio Marzano, Eugenia Veronica Di Brizzi, Matteo Megna, Giampiero Girolomoni, Claudio Guarneri, Emanuele Trovato, Emanuele Cozzani, Claudia Lasagni, Massimo Travaglini, Lidia Sacchelli, Valentina Dini, Antonio Costanzo, Anna Balato, Luca Potestio, Martina Burlando, Mario Valenti, Alessandra Michelucci, Luciano Ibba, Andrea Carugno, Nicola Zerbinati, Francesca Maria Gaiani, S. Di Giulio, Narcisi Alessandra, Carlo Giovanni Carrera, Federico Bardazzi, Piergiorgio Malagoli
article en

Abstract

INTRODUCTION: Phase III trials and their open-label extensions have established the efficacy of tildrakizumab in moderate-to-severe plaque psoriasis, but real-world evidence beyond 3 years of treatment is lacking. We assessed the long-term effectiveness, drug survival, and safety of tildrakizumab in routine clinical practice up to 5 years of follow-up. METHODS: A total of 1354 adult patients with moderate-to-severe psoriasis, treated with tildrakizumab for at least 16 weeks, were enrolled across 17 Italian Dermatology Units. Effectiveness was assessed as the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90, PASI 100, and absolute PASI ≤ 2 between week 16 and year 5. Drug survival was estimated by the Kaplan-Meier method, and multivariable logistic regression was used to identify baseline predictors of complete skin clearance. RESULTS: After 1 year of treatment, PASI 90, PASI 100, and PASI ≤ 2 were achieved by 74.0%, 57.2%, and 90.6% of patients, respectively, and responses were maintained through year 5 (87.3%, 76.2%, and 93.7%) in the 63 patients evaluable as observed. Overall drug survival was 92.0% at year 1 and 78.2% at year 5. A short disease duration was the only independent predictor of PASI 100, whereas obesity and cardiometabolic comorbidities did not impair response. No new safety signals emerged. CONCLUSIONS: In this 5-year real-world analysis, tildrakizumab maintained deep responses and high persistence across comorbid and difficult-to-treat subgroups, while short disease duration independently predicted complete clearance.

Dermatology and Therapy
University of Siena (IT), University of Pisa (IT), University of Messina (IT), University of Insubria (IT), University of Verona (IT), University of Modena and Reggio Emilia (IT), Humanitas University (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Unita' Sanitaria Locale Di Modena (IT), IRCCS Policlinico San Donato (IT), Ospedale A. Perrino (IT), Azienda Ospedaliero-Universitaria di Modena (IT), University of Campania "Luigi Vanvitelli" (IT), San Gallicano Hospital (IT), Ospedale Policlinico San Martino (IT), IRCCS Humanitas Research Hospital (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Genoa (IT), University of Bologna (IT)
Good health and well-being
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon